Paracetamol IV

Global Paracetamol IV Market to Reach US$866.5 Million by 2030

The global market for Paracetamol IV estimated at US$774.5 Million in the year 2024, is expected to reach US$866.5 Million by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Pain Indication, one of the segments analyzed in the report, is expected to record a 1.5% CAGR and reach US$592.8 Million by the end of the analysis period. Growth in the Pyrexia / Fever Indication segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.0 Million While China is Forecast to Grow at 3.7% CAGR

The Paracetamol IV market in the U.S. is estimated at US$211.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$161.6 Million by the year 2030 trailing a CAGR of 3.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Paracetamol IV Market – Key Trends & Drivers Summarized

Why Is the Paracetamol IV Market Experiencing Steady Growth?

The intravenous (IV) paracetamol market is growing due to the increasing demand for effective pain management solutions in hospital and surgical settings. IV paracetamol is widely used for post-operative pain relief, trauma care, and fever management, offering a fast-acting alternative to oral analgesics. Its ability to provide effective pain relief without the opioid-related risks of addiction and respiratory depression is making it a preferred choice in acute care settings.

Additionally, the rising number of surgeries, emergency room visits, and intensive care unit (ICU) admissions is fueling demand for IV paracetamol. With growing concerns about opioid misuse and regulatory restrictions on opioid prescribing, healthcare providers are turning to non-opioid pain management options, further driving market expansion.

How Are Formulation and Drug Delivery Innovations Enhancing IV Paracetamol?

Advancements in IV paracetamol formulations are improving drug stability, bioavailability, and infusion compatibility. Extended-release and high-concentration formulations are being developed to optimize dosing efficiency and reduce the frequency of administration. Additionally, ready-to-use IV paracetamol solutions are streamlining hospital workflows, reducing preparation time, and minimizing the risk of medication errors.

Another key innovation is the integration of IV paracetamol into multimodal analgesia protocols, which combine non-opioid and opioid analgesics to enhance pain relief while minimizing side effects. This approach is gaining traction in surgical recovery and critical care management, contributing to market growth.

Is the Shift Toward Non-Opioid Pain Management Driving Market Demand?

The global push to reduce opioid dependency is a major driver of the IV paracetamol market. Governments and healthcare institutions are actively promoting non-opioid alternatives for pain management to combat the opioid crisis. IV paracetamol is being increasingly recommended in perioperative care and post-surgical recovery, reducing the need for opioid analgesics.

Additionally, clinical guidelines emphasizing enhanced recovery after surgery (ERAS) protocols are incorporating IV paracetamol as a key component of non-opioid pain management strategies. This shift is leading to increased adoption in orthopedic, cardiovascular, and gastrointestinal surgeries.

What’s Driving the Growth of the IV Paracetamol Market?

The growth in the IV paracetamol market is driven by increasing surgical procedures, rising demand for opioid-free pain management, and advancements in drug formulation and delivery systems. Regulatory support for non-opioid analgesics is further accelerating market adoption.

Additionally, the expansion of hospital infrastructure, improved access to critical care, and the integration of IV paracetamol into multimodal pain management protocols are fueling demand. As healthcare systems continue to prioritize patient safety and opioid reduction strategies, the IV paracetamol market is expected to see sustained growth.

SCOPE OF STUDY:

The report analyzes the Paracetamol IV market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Indication (Pain Indication, Pyrexia / Fever Indication); Application (Surgical Application, Non-surgical Application); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• AdvaCare Pharma
• Anhui Shinecare Co., Ltd.
• Arrier Biotech Pvt Ltd
• Aurobindo Pharma
• B. Braun Melsungen AG
• Bristol-Myers Squibb Company
• Cipla Inc.
• Dr. Reddy`s Laboratories Ltd.
• Eurocrit Labs
• Gnova Biotech
• Granules India Limited
• Guangzhou Sinolead Biotech Co., Ltd.
• Hainan Seafort Healthcare Ltd
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.